Paper Details

  1. Home
  2. Paper Details

Repotrectinib Exhibits Potent Antitumor Activity in Treatment-Naïve and Solvent-Front-Mutant ROS1-Rearranged Non-Small Cell Lung Cancer.

Author: ChoByoung Chul, ChoiHun Mi, CuiJ Jean, DrilonAlexander, HeoSeong Gu, HongMin Hee, JooHyeong-Seok, KangHan Na, KangSeok-Gu, KimDong Hwi, KimHye Ryun, KimSeok-Young, LeeSung Sook, LeeYou Won, ParkChae Won, SchoenfeldAdam J, ShimHyo Sup, YunMi Ran

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

This study investigated the antitumor activity of repotrectinib, a novel next-generation ROS1/TRK/ALK-tyrosine kinase inhibitor (TKI), in ROS1+ patient-derived preclinical models. Repotrectinib showed promising antitumor activity against crizotinib-resistant ROS1-G2032R (ROS1G2032R) mutation and CNS progression.
Paper Details　
Original Abstract of the Article :
Label="PURPOSE">Although first-line crizotinib treatment leads to clinical benefit in <i>ROS1<sup>+</sup></i> lung cancer, high prevalence of crizotinib-resistant ROS1-G2032R (ROS1<sup>G2032R</sup>) mutation and progression in the central nervous system (CNS) represents a therapeutic challenge. Here...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://pubmed.ncbi.nlm.nih.gov/32269053

データ提供：米国国立医学図書館（NLM）

Repotrectinib in ROS1-Rearranged Lung Cancer: A New Oasis in the Desert of Treatment

The fight against cancer is a relentless journey, with researchers constantly seeking new and effective treatments. This study delves into the potential of repotrectinib, a novel next-generation tyrosine kinase inhibitor (TKI), in treating ROS1-rearranged non-small cell lung cancer (NSCLC). The researchers investigated the antitumor activity of repotrectinib in both treatment-naive and crizotinib-resistant ROS1-positive patient-derived preclinical models. Their findings suggest that repotrectinib exhibits potent antitumor activity in both settings, offering a promising therapeutic option for patients with ROS1-rearranged NSCLC.

A New Path Through the Desert of Resistance

This study demonstrates the effectiveness of repotrectinib in overcoming crizotinib resistance, a significant challenge in treating ROS1-rearranged NSCLC. The researchers observed significant antitumor activity in both treatment-naive and crizotinib-resistant models, highlighting the potential of repotrectinib as a valuable therapeutic option for patients facing resistance to other TKIs.

Finding the Oasis of Effective Treatment

The discovery of new and effective treatments for cancer is a vital pursuit, and this study offers a glimmer of hope for patients with ROS1-rearranged NSCLC. The promising results with repotrectinib suggest a potential pathway toward more effective and targeted therapies for this type of cancer. Further research is needed to fully understand the efficacy and safety of repotrectinib in clinical settings.

Dr. Camel's Conclusion

Just as a camel seeks out a hidden oasis in the vast and unforgiving desert, researchers are constantly searching for new therapies to combat the challenges of cancer. This study offers a promising new path in the fight against ROS1-rearranged NSCLC, highlighting the potential of repotrectinib as a powerful weapon in the arsenal of oncologists.

Date :
  1. Date Completed 2021-09-14
  2. Date Revised 2023-07-01
Further Info :

Pubmed ID

32269053

DOI: Digital Object Identifier

NIHMS1566218

Related Literature

Article Analysis
・Effects of repotrectinib
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.